Print
Professionals
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Name
Advanced Search…
Government Experience…
Practices & Industries
Litigation & Trial
Regulatory & Policy
Transactions & Corporate
Investigations
Digital Transformation
Coronavirus Resource Center
Industries
C&M International
View All Practices & Industries
Locations
Brussels
Doha
London
Los Angeles
New York
Orange County
San Francisco
Shanghai
Washington, D.C.
C&M International
Singapore
Washington, D.C.
News & Events
Events
Firm News & Announcements
Client Alerts & Newsletters
Media Mentions
Publications
Social Media & Blogs
Speeches & Presentations
Podcasts
Creating Tomorrow Series
Coronavirus Resource Center
Biden First 100 Days
Litigation Forecast 2021
About
Overview
Leadership
History
Awards
Innovation in Service
Diversity & Inclusion
Pro Bono
Careers
Lawyers
Law Students
Professionals
Professionals
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Name
Location
All Locations
Brussels
Doha
London
Los Angeles
New York
Orange County
San Francisco
Shanghai
Singapore
Washington, D.C.
Practice
All Practices
Litigation & Trial
Regulatory & Policy
Transactions & Corporate
Administrative Law & Regulatory
Advertising & Media
Antitrust & Competition
Appellate
Arbitration
Aviation
Bankruptcy & Creditors' Rights
Blockchain / Distributed Ledger Technology (DLT)
Broker-Dealer
Business Aviation
C&M International
Class Actions
Commercial Contracts & Outsourcing
Commercial Finance & Lending
Commercial Litigation
Commercial Real Estate
Coronavirus (COVID-19) Response Team
Corporate
Corporate Counseling, Governance & Compliance
Corporate Finance & Securities
Digital Health/MedTech
Digital Transformation
E-Discovery & Information Management
Education
Emerging Companies & Venture Capital
Energy
Environment & Natural Resources
ERISA & Employee Benefits
European (EU) Regulatory
Executive Practice
False Claims Act
Financial Institutions
Financial Services
Foreign Corrupt Practices Act
Government Affairs
Government Contracts
Government Contracts Transactions
Health Care
Hedge Funds / Investment Funds
Infrastructure
Insurance/Reinsurance
Intellectual Property Litigation
International Dispute Resolution
International Trade
Investigations
Investigations: Government & Internal
IP Prosecution & Regulatory
IP Transactions & Portfolio Management
Israel Practice
Joint Ventures & Strategic Alliances
Labor & Employment
Latin America Practice
Legal Ethics & Malpractice
Mass Tort, Product, and Consumer Litigation
Mergers & Acquisitions
Middle East and North Africa (MENA) Practice
National Coordinating Counsel & Complex Litigation
National Security
Nonprofit & Tax-Exempt Organizations
Pharmaceuticals & Life Sciences
Plaintiff's Recovery
Privacy & Cybersecurity
Private Equity
Product Risk Management
Public-Private Partnerships
Restructuring & Creditors' Rights
SEC Enforcement
State Attorneys General Practice
Tax
Trade Secrets
Transportation
Trial
Whistleblower
White Collar & Regulatory Enforcement
Industry
All Industries
3D Printing
Aerospace & Defense
Agriculture
Artificial Intelligence and Robotics
Automotive & Trucking
Autonomous Vehicles
Aviation
Chemicals
Education
Financial Services
Food & Beverage
Government Contracts
Health Care
Hospitality & Leisure
Insurance/Reinsurance
Mining
Pharmaceuticals & Life Sciences
Retail & Consumer Products
Technology, Media & Telecommunications
Trade Associations
Transportation
Advanced Search…
Government Experience…
Practices & Industries
Litigation & Trial
Regulatory & Policy
Transactions & Corporate
Investigations
Digital Transformation
Coronavirus Resource Center
Industries
C&M International
View All Practices & Industries
Search By Name
Locations
Brussels
Doha
London
Los Angeles
New York
Orange County
San Francisco
Shanghai
Washington, D.C.
C&M International
Singapore
Washington, D.C.
News & Events
Events
Firm News & Announcements
Client Alerts & Newsletters
Media Mentions
Publications
Social Media & Blogs
Speeches & Presentations
Podcasts
Creating Tomorrow Series
Coronavirus Resource Center
Biden First 100 Days
Litigation Forecast 2021
About
Overview
Leadership
History
Awards
Innovation in Service
Diversity & Inclusion
Pro Bono
Careers
Lawyers
Law Students
Professionals
Intellectual Property Litigation
Professionals
Contacts
Representative Engagements
News & Events
Focus Areas
Antitrust & Competition Law
Copyright
European IP Practice
Patent Litigation
Pharmaceutical &
Biologics Litigation
Post-Issuance Proceedings
TLDs & Domain Names
Trade Secrets
Trademarks & Brand Protection
U.S. International Trade Commission Section 337 Unfair Import Investigations
IP Prosecution & Regulatory
IP Transactions & Portfolio Management
Related Services
C&M International
Pharmaceuticals & Life Sciences Industry
Trade Secrets & Insider Threats Investigations
Practices
›
Intellectual Property Litigation
›
Pharmaceutical & Biologics Litig…
›
Representative Engagements
Pharmaceutical & Biologics Litigation
Representative Engagements
Pfizer, Inc., et al. v. Watson Laboratories, Inc.- Florida.
Representing Watson in patent infringement action involving a generic version of Embeda® (sulfate and naltrexone hydrochloride).
Watson Pharmaceuticals, Inc.
,
et al. v. Bayer Pharma AG, et al.
Representing Watson in malicious prosecution action against Bayer alleging it improperly enforced patents against a generic version of Yasmin
®
(drospirenone and ethinyl estradiol) oral contraceptive product.
The Howard-Florey Institute v. Kleiner, Perkins et al.
Representing Plaintiff
Howard Florey Institute of Neurosciences in dispute over licensing of its IP rights in relaxin and related polypeptides.
MorphoSys v. Cambridge Antibody Technology (CAT).
Successfully tried a three-week biotech patent jury trial regarding phage display antibody library technology which is the core intellectual property in Abbott's Humira® biologic. CAT's antibody patents were upheld against claims of invalidity.
Takeda Pharmaceutical, Co., Ltd., et al. v. Handa Pharmaceuticals, LLC and Par Pharmaceutical, Inc.
Represented Par in six-day bench trial in patent infringement action involving a generic version of Dexilant® (dexlansoprazole).
Shire Development LLC, et al. v. Watson Pharmaceuticals, Inc., et al.
Represented Watson in five-day bench trial in patent infringement action involving a generic version of Lialda® (mesalamine).
Bayer HealthCare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc.
Represented Watson in patent infringement action involving a generic version of Yaz® (drospirenone and ethinyl estradiol) oral contraceptive product. Successfully appealed to the Federal Circuit resulting in reversal of adverse summary judgment of non-obviousness and a holding by the appeals court invalidating Bayer's patent.
In Re Armodafinil Patent Litigation (MDL).
Lead MDL trial counsel representing first-filer Mylan in ANDA litigation involving a generic version of Nuvigil® (armodafinil). Defeated motion for temporary restraining order and preliminary injunction, and obtained a favorable settlement.
Bayer Schering Pharma AG, et al. v. Sandoz Inc., et al
. Represented Watson in ANDA litigation involving a generic version of Yasmin® (drospirenone and ethinyl estradiol) oral contraceptive product. Defeated motion to extend the 30-month stay, resulting in defendant's successful at-risk launch. Obtained Rule 12(c) defense judgment on the pleadings of non-infringement that Bayer's asserted patent did not cover the FDA-approved use of the drug. Argued and obtained affirmance of non-infringement at the Federal Circuit.
Cephalon Inc. and CIMA Labs, Inc. v. Watson Pharmaceuticals, Inc. et al.
Represented first-filer Watson in a patent infringement action involving a generic version of Fentora® (fentanyl citrate) resulting in a trial court entering judgment of invalidity and non-infringement on both Orange Book-listed patents. Federal Circuit reversed on invalidity and affirmed non-infringement.
Duramed Pharmaceuticals Inc. v. Watson Laboratories Inc.
Represented first-filer Watson in a patent infringement action involving a generic version of Seasonique® (ethinyl estradiol and levonorgestrel) resulting in successful at-risk launch. Obtained reversal by Federal Circuit of the district court's grant of summary judgment of no invalidity, and defeated subsequent motion for temporary restraining order and preliminary injunction, including defending same successfully at Federal Circuit after emergency and expedited appeals.
Teva Women's Health Inc. v. Lupin Ltd., et al.
Represented first-filer Watson in patent infringement action involving a generic version of LoSeasonique® (ethinyl estradiol and levonorgestrel) oral contraceptive product and obtained favorable settlement prior to defendant's filing of motion for summary judgment.